



FOR IMMEDIATE RELEASE

Immgenuity Appoints Dr. Richard Ogden to its Board of Directors and Scientific Advisory Board

Dover, Delaware, January 28, 2023 - Immgenuity, a leading biotechnology company specializing in the development of an innovative immunotherapy for HIV, announced today that Dr. Richard Ogden has joined the company's Scientific Advisory Board and Board of Directors.

Since leaving Pfizer in April 2006, Dr. Ogden co-founded RORR Inc., a Medical, Scientific Consulting and Education company with current US and European-based clients. Areas of corporate focus include, viral infectious diseases (HIV, Hepatitis C, Respiratory viruses); strategic planning for clinical research programs; product development in the antiviral and oncology therapeutic areas; biological product development in the analytical reagents and tools area; manufacturing and engineering liaison; intellectual property consultancy; technology feasibility assessment; and fund raising on behalf of new biotechnology companies. Dr. Ogden has consulted and advised numerous life sciences companies, all at various stages of development in the field of HIV and HCV therapeutics.

Dr. Ogden's decades of experience in the field of infectious diseases goes back to Agouron Pharmaceuticals, Inc. where he was as a founding scientist in 1984. He was a team member in the HIV project which led to the discovery and development of Nelfinavir (Viracept®). Dr. Ogden served as the scientific liaison for the Agouron / Pfizer commercial and corporate organizations following the merger with Pfizer, and his principal responsibilities have included assisting in the continued support of the protease inhibitor Nelfinavir, by providing medical education, including CME certified presentations, within the HIV/AIDS clinical and patient communities, and in the evaluation of proposals for post marketing clinical research in the HIV/AIDS area.

Dr. Ogden was also a senior advisor to Hank McKinnell, then CEO of Pfizer, during McKinnell's leadership at the Presidential Advisory Commission on HIV/AIDS ("PACHA"). Dr. Ogden served with both Agouron and Pfizer as the representative on the International AIDS Society Industry Liaison Forum. In addition to numerous publications, he is co-editor, with Charles Flexner, on a book on Protease Inhibitors in AIDS Therapy and with Gail Skowron, on a book on Reverse Transcriptase Inhibitors in AIDS Therapy.

"We are thrilled to welcome Dr. Ogden to Immgenuity's Scientific Advisory Board and Board of Directors. His extensive knowledge and expertise in the field of HIV Therapeutics and drug development will be invaluable as we continue to develop innovative approach to HIV remission with our therapeutic vaccine platform.", said Dr. Sateesh Apte, Immgenuity's CEO.

Dr. Ogden stated, “I am excited to join Immgenuity’s Scientific Advisory Board and Board of Directors. Immgenuity has made significant progress in the development of a novel therapy for HIV, and I look forward to contributing to the company’s mission.”

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company’s lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity’s immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.